Parvovirus infection mimicking systemic lupus erythematosus

CMAJ. Canadian Medical Association Journal

Volumn 185, Issue 15, 2013, Pages 1342-1344

  Cooray, Mohan ^a   Manolakos, Joshua J ^a   Wright, Douglas S ^a   Haider, Shariq ^a   Patel, Ameen ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINUCLEAR ANTIBODY; CARDIOLIPIN ANTIBODY; COMPLEMENT; COMPLEMENT COMPONENT C4; IMMUNOGLOBULIN M; RHESUS ANTIGEN;

ADULT; ANAMNESIS; ANTIBODY DETECTION; ANTIBODY TITER; ARTHRALGIA; ARTICLE; CASE REPORT; DIFFERENTIAL DIAGNOSIS; FEMALE; HUMAN; HUMAN PARVOVIRUS B19; HYPOCOMPLEMENTEMIA; LYMPHOCYTE COUNT; PARVOVIRUS INFECTION; PRURITUS; RASH; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTE COUNT; THROMBOCYTOPENIA;

EID: 84886399574     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: 10.1503/cmaj.121565     Document Type: Article

References (19)

1. Heegaard ED, Brown KE. Human parvovirus B19. Clin Microbiol Rev 2002;15:485-505.
2. Lamont RF, Sobel JD, Vaisbuch E, et al. Parvovirus B19 infection in human pregnancy. BJOG 2011;118:175-86.
3. Anderson MJ, Higgins PG, Davis LR, et al. Experimental parvoviral infection in humans. J Infect Dis 1985;152:257-65.
4. Brown KE, Young NS. Parvovirus B19 in human disease. Annu Rev Med 1997;48:59-67.
5. Young NS, Brown KE. Parvovirus B19. N Engl J Med 2004; 350: 586-97.
6. Speyer I, Breedveld FC, Dijkmans BA. Human parvovirus B19 infection is not followed by inflammatory joint disease during long term follow-up. A retrospective study of 54 patients. Clin Exp Rheumatol 1998;16:576-8.
7. Risks associated with human parvovirus B19 infection. MMWR Morb Mortal Wkly Rep 1989; 38: 81-8.
8. Erdman DD, Usher MJ, Tsou C, et al. Human parvovirus B19 specific IgG, IgA, and IgM antibodies and DNA in serum specimens from persons with erythema infectiosum. J Med Virol 1991; 35:110-5.
9. Enders M, Weidner A, Rosenthal T, et al. Improved diagnosis of gestational parvovirus B19 infection at the time of nonimmune fetal hydrops. J Infect Dis 2008;197:58-62.
10. Broliden K, Tolfyenstam T, Norbeck O. Clinical aspects of parvovirus B19 infection. J Intern Med 2006;260:285-304.
11. Soloninka CA, Anderson MJ, Laskin CA. AntiDNA and antilymphocyte antibodies during acute infection with human parvovirus B19. J Rheumatol 1989;16:777-81.
12. Meyer O. Parvovirus B19 and autoimmune diseases. Joint Bone Spine 2003;70:6-11.
13. Moore TL. Parvovirus-associated arthritis. Curr Opin Rheumatol 2000;12:289-94.
14. Sève P, Ferry T, Koenig M, et al. Lupus-like presentation of parvovirus B19 infection. Semin Arthritis Rheum 2005;34:642-8.
15. Solomon DH, Kavanaugh AJ, Schur PH, et al. Evidence-based guidelines for the use of immunologic tests: antinuclear antibody testing. Arthritis Rheum 2002;47:434-44.
16. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25:1271-77.
17. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997;40:1725.
18. Aletaha D, Neogi T, Silman AJ, et al. 2010 Rheumatoid arthritis classification criteria. Arthritis Rheum 2010;62:2569-81.
19. Severin MC, Levy Y, Shoenfeld Y. Systemic lupus erythematosus and parvovirus B19: Casual coincidence or causative culprit? Clin Rev Allergy Immunol 2003;25:41-8.